ERBB2 and breast adenocarcinoma: Simultaneous or staggered inhibition of EGFR (over-expressed) and HER2/neu (highly over-expressed) function on the external surface membrane of mammary adenocarcinoma (SKBr-3) utilizing multiple covalent immunochemotherapeutics represents an approach for attaining additive and synergistic levels of anti-neoplastic efficacy.